Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman, Barry J Goldstein, Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman, Barry J Goldstein

Abstract

Background: In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated compared with treatment with control agents. As clinical development of sitagliptin continues, additional studies have been completed, and more patients have been exposed to sitagliptin. The purpose of the present analysis is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies.

Methods: The present analysis included data from 10,246 patients with type 2 diabetes who received either sitagliptin 100 mg/day (N = 5,429; sitagliptin group) or a comparator agent (placebo or an active comparator) (N = 4,817; non-exposed group). The 19 studies from which this pooled population was drawn represent the double-blind, randomized studies that included patients treated with the usual clinical dose of sitagliptin (100 mg/day) for between 12 weeks and 2 years and for which results were available as of July 2009. These 19 studies assessed sitagliptin taken as monotherapy, initial combination therapy with metformin or pioglitazone, or as add-on combination therapy with other antihyperglycemic agents (metformin, pioglitazone, a sulfonylurea +/- metformin, insulin +/- metformin, or rosiglitazone + metformin). Patients in the non-exposed group were taking placebo, metformin, pioglitazone, a sulfonylurea +/- metformin, insulin +/- metformin, or rosiglitazone + metformin. The analysis used patient-level data from each study to evaluate between-group differences in the exposure-adjusted incidence rates of adverse events.

Results: Summary measures of overall adverse events were similar in the sitagliptin and non-exposed groups, except for an increased incidence of drug-related adverse events in the non-exposed group. Incidence rates of specific adverse events were also generally similar between the two groups, except for increased incidence rates of hypoglycemia, related to the greater use of a sulfonylurea, and diarrhea, related to the greater use of metformin, in the non-exposed group and constipation in the sitagliptin group. Treatment with sitagliptin was not associated with an increased risk of major adverse cardiovascular events.

Conclusions: In this updated pooled safety analysis of data from 10,246 patients with type 2 diabetes, sitagliptin 100 mg/day was generally well tolerated in clinical trials of up to 2 years in duration.

References

    1. Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP. et al.Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14. doi: 10.1186/1472-6823-8-14.
    1. McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation. 2008;117:440–449. doi: 10.1161/CIRCULATIONAHA.107.704080.
    1. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52:1699–1708. doi: 10.1007/s00125-009-1441-5.
    1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360–372. doi: 10.1001/jama.287.3.360.
    1. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation. 2008;117:574–584. doi: 10.1161/CIRCULATIONAHA.107.735795.
    1. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169:1395–1402. doi: 10.1001/archinternmed.2009.214.
    1. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820–825. doi: 10.1001/archinte.168.8.820.
    1. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516–523. doi: 10.1161/HYPERTENSIONAHA.109.134197.
    1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206. doi: 10.1001/jama.298.2.194.
    1. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009. in press .
    1. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171–180. doi: 10.1111/j.1742-1241.2006.01246.x.
    1. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23:1329–1339. doi: 10.1185/030079907X188152.
    1. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987. doi: 10.2337/dc07-0627.
    1. Reasner CA, Olansky L, Seck T, Williams-Herman D, Luo E, Chen M. et al.Initial therapy with the fixed-dose combination (FDC) if sitagliptin and metformin (JANUMET) in patients with type 2 diabetes mellitus provides superior glycaemic control and HbA1c goal attainment with lower rates of abdominal pain and diarrhea vs metformin alone (abstract) Diabetologia. 2009;52(Suppl 1):S295.
    1. Olansky L, Reasner CA, Seck T, Williams-Herman D, Luo E, Chen M. et al.A strategy implementing initial therapy with a fixed-dose combination tablet of sitagliptin and metformin in patients with type 2 diabetes provides superior glycemic control compared with a strategy using initial metformin monotherapy over 44 weeks (abstract) IDF Abstract Book. 2009;0-0535:178.
    1. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ. et al.Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10:545–555. doi: 10.1111/j.1463-1326.2008.00914.x.
    1. Guidance for Industry: Collection of race and ethnicity data in clinical trials. 9/2/2005. (last accessed February 9, 2010).
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226. doi: 10.1002/sim.4780040211.
    1. Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. in press .
    1. Breslow NE, Day NE. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987. pp. 1–406.
    1. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics. 1986;42:311–323. doi: 10.2307/2531052.
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG. et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31. doi: 10.1186/cc5713.
    1. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205. doi: 10.1111/j.1463-1326.2006.00704.x.
    1. Seck T, Nauck MA, Sheng D, Sunga S, Davies MJ, Stein PP. et al.Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract. 2010;64:562–576. doi: 10.1111/j.1742-1241.2010.02353.x.
    1. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–745. doi: 10.1111/j.1463-1326.2007.00744.x.
    1. Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E. et al.Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167–177. doi: 10.1111/j.1463-1326.2009.01173.x.
    1. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008;24:489–496. doi: 10.1185/030079908X261069.
    1. Alba M, Ahren B, Inzucchi SE, Guan Y, Mallick M, Xu L. et al.Initial combination therapy with sitagliptin and pioglitazone: complementary effects on postprandial glucose and islet cell function (abstract) IDF Abstract Book. 2009;P-1740:584.
    1. Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG. et al.Sitagliptin and pioglitazone initial combination therapy in patients with type 2 diabetes provides substantial and durable incremental improvement in glycemic control over one year compared with initial treatment with pioglitazone monotherapy (abstract) IDF Abstract Book. 2009;P-1153:391.
    1. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262–269. doi: 10.1038/nrendo.2009.48.
    1. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML. et al.Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56:1475–1480. doi: 10.2337/db07-0136.
    1. Stevens JE, Maddox AF, Wolthers T, Deacon C, Nauck M, Rayner CK, Sitagliptin has no effect on gastric emptying in healthy humans (abstract) Australian Diabetes Society. 2009. abstract # 95.
    1. Hellstrom PM. GLP-1: broadening the incretin concept to involve gut motility. Regul Pept. 2009;156:9–12. doi: 10.1016/j.regpep.2009.04.004.
    1. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008. p. CD006739.
    1. Kimmel D, Cusick T, Mu J, Pennypacker B, Shen XL, Li ZH. et al.Thiazolidinediones, but not sitagliptin, exacerbate ovariectomy-induced bone loss in rats (abstract) Diabetes. 2009;58(Suppl 1):A374.
    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404.
    1. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Mortality results. Diabetes. 1970;19(Suppl 1):789–830.
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471. doi: 10.1056/NEJMoa072761.
    1. Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (abstract) Diabetologia. 2009;52(Suppl 1):S480.
    1. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132:2208–2225. doi: 10.1053/j.gastro.2007.03.050.
    1. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22:571–588. doi: 10.1016/j.bpobgyn.2008.04.002.
    1. Pandya KA, Radke F. Benign skin lesions: lipomas, epidermal inclusion cysts, muscle and nerve biopsies. Surg Clin North Am. 2009;89:677–687. doi: 10.1016/j.suc.2009.03.002.
    1. European Medicines Agency (EMEA): Galvus (vildagliptin) - European Public Assessment Report (EPAR) - Scientific Discussion. 2007. (last accessed February 9, 2010).
    1. European Medicines Agency (EMEA): Onglyza (saxagliptin) - European Public Assessment Report (EPAR) - CHMP Assessment Report. 2009. (last accessed February 9, 2010).
    1. European Medicines Agency (EMEA): Januvia (sitagliptin) - European Public Assessment Report (EPAR) - Scientific Discussion. 2007. (last accessed February 9, 2010).
    1. Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T. et al.Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007;120:403–408. doi: 10.1016/j.jaci.2007.04.012.
    1. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J. et al.Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51:141–147. doi: 10.1161/HYPERTENSIONAHA.107.096552.
    1. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–1568. doi: 10.1016/j.clinthera.2006.10.007.
    1. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–2643. doi: 10.2337/dc06-0706.
    1. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–2637. doi: 10.2337/dc06-0703.
    1. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564–2571. doi: 10.1007/s00125-006-0416-z.
    1. Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD. et al.Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25:569–583. doi: 10.1185/03007990802705679.
    1. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ. et al.Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442–451. doi: 10.1111/j.1463-1326.2010.01204.x.
    1. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB. et al.Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83:106–116. doi: 10.1016/j.diabres.2008.10.009.
    1. Barzilai N, Mahoney EM, Guo H, Golm GT, Williams-Herman D, Kaufman KD, Sitagliptin monotherapy is an effective and well-tolerated treatment for type 2 diabetes in elderly patients (abstract) 61st Annual Scientific Meeting of the Gerontological Society of America. 2008.
    1. Aschner P, Katzeff H, Guo H, Sunga S, Williams-Herman D, Kaufman KD. et al.Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:252–261. doi: 10.1111/j.1463-1326.2009.01187.x.
    1. Dobs A, Goldstein BJ, Wieczorek L, Golm G, Davies MJ, Williams-Herman D. et al.Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycemic control in patients with type 2 diabetes (abstract) Diabetes. 2008;57(Suppl 1):A595–A596.
    1. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM. et al.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24:537–550. doi: 10.1185/030079908X260925.
    1. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959–969. doi: 10.1111/j.1463-1326.2007.00839.x.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren